Statins side effects: 'Pink-red blotches' considered serious side effect - 'call a doctor'
STATINS are a group of medicines that can help lower the level of cholesterol in the blood. However, with treatments like statins come side effects - the NHS warn that a skin rash with pink-red blotches, especially on the palms of the hands or soles of the feet could appear if you take statins.
Antiplatelet agents and statins have improved the medical management of internal carotid artery (ICA) stenosis since the publication of the ACAS trial. Yet, little is published about the natural history of medically managed patients with carotid stenosis. Stroke incidence and mortality associated with carotid stenosis remains high in the southeastern US. We sought to determine the outcomes of patients diagnosed with>70% ICA stenosis treated with medical management alone.
Epidemiological studies on statin use in relation to skin cancer risk are scarce and yielded conflicting results. We explored this association in E3N, a prospective cohort of French women born in 1925-1950. Health and lifestyle data were self-reported biennially and matched with drug reimbursement data allowing to identify participants ’ statin use since 2004. Multivariable cause-specific hazards regression models adjusted for skin cancer risk factors estimated hazard ratios (HRs) with 95% confidence intervals (CIs).
By HANS DUVEFELT I happened to read about the pharmacodynamics of parenteral versus oral furosemide when I came across a unique interaction between this commonest of diuretics and risperidone: Elderly dementia patients on risperidone have twice their expected mortality if also given furosemide. I knew that all atypical antipsychotics can double mortality in elderly dementia patients, but was unaware of the additional risperidone-furosemide risk. Epocrates only has a nonspecific warning to monitor blood pressure when prescribing both drugs. This is only today’s example of an interaction I didn’t ...
Conclusions: Continuous and binary trajectory models are conceptually different measures of medication adherence. The choice between these approaches should be guided by study objectives and the role of medication adherence within the study—exposure, outcome, or confounder.
Katsanos et al. conducted a meta-analysis to investigate the association between statin treatment and cerebral microbleeds (CMBs) . The adjusted odds ratios (95% confidence intervals [CIs]) of statin treatment for all- and lobar CMBs were 1.09 (0.64 –1.86) and 2.26 (0.86–5.91), respectively. As there was a heterogeneity in this analysis, the authors recommended further investigation. I have a comment regarding the study.
We appreciate Dr. Kawada for his interest in our systematic review and meta-analysis investigating the association between statin treatment and cerebral microbleeds (CMBs) . In this systematic review and meta-analysis we analyzed cross-sectional evidence from available cohorts nested within randomized-controlled clinical trials or observational studies . In the overall analysis statin treatment was not found to be associated with CMBs presence, but when the analysis was restricted to lobar CMBs the association between statin use and the probability for lobar CMBs presence was positive .
Conclusions: The use of statins does not seem to influence the functional outcome in post-stroke patients. However, they could exert a protective role against bone fractures during post-discharge follow-up, suggesting further evaluation on this topic.
In conclusion, PCSK9i added to background statins may be recommended as preferred lipid-lowering therapy, and did not increase the additional risk of new-onset diabetes. The safety and efficacy of ezetimibe was not superior to that of statins. LT can be recommended as the initial therapy.
CONCLUSIONS: Preprocedural biomarkers, such as CRP and HbA1c, are associated with long-term mortality post revascularisation, regardless of the revascularisation technique. Conventional lipidic biomarkers associated with high-risk of cardiovascular events seem to be effectively mitigated by the long-term use of statins, whereas the non-use of statins was a factor of a worse prognosis, emphasising the importance of pharmacological treatment.TRIAL REGISTRATION: SYNTAXES ClinicalTrials.gov reference: NCT03417050. SYNTAX ClinicalTrials.gov reference: NCT00114972.PMID:34669586 | DOI:10.4244/EIJ-D-21-00415
This study investigates the effects of colchicine and rosuvastatin on TF expression in oxLDL-activated T-cells. T-cells, isolated from buffy coats of healthy volunteers, were stimulated with oxLDL (50 µg/dL). T-cells were pre-incubated with colchicine (10 µM) or rosuvastatin (5 µM) for 1 h and then stimulated with oxLDL (50 μg/mL). TF gene (RT-PCR), protein (western blot), surface expression (FACS) and procoagulant activity (FXa generation assay) were measured. NF-κB/IκB axis was exam ined by western blot analysis and translocation assay. Colchicine and rosuvastati...